drugset
drugset / Trial / NCT04527081

Study of COVID-19 DNA Vaccine (AG0302-COVID19)

NCT04527081 ↗

Phase 1/2 Completed 30 enrolled AnGes, Inc.
RandomizedParallel-groupOpen-labelPrevention

Summary

This study will assess the safety and immunogenicity of AG0302-COVID19 in healthy adult volunteers.

Timeline

Start
2020-08-31
Primary completion
2020-11-09
Completion
2021-09-24

Drugs

EvaluationDrugModalityDoseRoute
Subject AG0302-COVID19 Vaccine 2 mg Intramuscular

Indications

COVID-19